Luyan Pharma Co.,Ltd. (SHE:002788)

Luyan Pharma Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	457.88	576.85	606.3	594.19	415.43	596.92
Cash & Short-Term Investments	457.88	576.85	606.3	594.19	415.43	596.92
Cash Growth	-0.06%	-4.86%	2.04%	43.03%	-30.40%	39.16%
Accounts Receivable	6,274	5,951	5,673	5,849	5,101	3,935
Other Receivables	117.52	108.33	94.59	87.49	117.17	269.68
Receivables	6,391	6,059	5,768	5,937	5,218	4,205
Inventory	2,625	2,865	2,574	2,549	2,275	2,028
Prepaid Expenses	-	0.02	0.25	0.33	0.08	0.25
Other Current Assets	359.57	369.1	370.33	668.17	414.12	378.69
Total Current Assets	9,833	9,870	9,319	9,748	8,322	7,209
Property, Plant & Equipment	1,957	1,928	1,653	1,425	1,037	845.53
Long-Term Investments	53.48	53.41	48.85	34.21	31.3	0.3
Goodwill	289.28	289.28	288.65	289.45	289.45	283.88
Other Intangible Assets	359.45	361.09	355.16	176.93	167.81	113.23
Long-Term Deferred Tax Assets	78.92	75.79	66.37	54.71	43.39	35.11
Long-Term Deferred Charges	28.34	29.04	28.58	28.96	32.82	33.73
Other Long-Term Assets	28.47	31.5	34.46	26.08	68.98	50.73
Total Assets	12,629	12,639	11,794	11,784	9,993	8,571
Accounts Payable	3,736	4,004	3,444	3,258	2,410	2,006
Accrued Expenses	36.39	86.74	98.53	119.54	111.6	103.73
Short-Term Debt	4,071	3,875	3,990	4,455	4,130	3,362
Current Portion of Long-Term Debt	317.66	293.91	171.26	58.25	47.31	21.31
Current Portion of Leases	-	46.67	43.54	37.98	41.69	-
Current Income Taxes Payable	56.75	36.67	43.98	43.47	45.42	44.26
Current Unearned Revenue	38.54	30.72	22.38	31.78	10.57	18.73
Other Current Liabilities	280.55	232.47	211.84	296.53	217.69	353.98
Total Current Liabilities	8,536	8,605	8,026	8,301	7,015	5,910
Long-Term Debt	635.11	648.41	578.63	475.04	226.6	116.94
Long-Term Leases	109.04	87.33	74.33	53.86	40.37	-
Long-Term Unearned Revenue	38.72	38.83	39.76	41.2	41.85	11.5
Long-Term Deferred Tax Liabilities	6.45	6.54	6.81	7.07	7.34	7.63
Other Long-Term Liabilities	40.64	60.14	90.98	114.97	101.17	77.27
Total Liabilities	9,366	9,447	8,817	8,993	7,433	6,124
Common Stock	388.52	388.52	388.52	388.52	388.52	388.52
Additional Paid-In Capital	617.54	617.54	631.05	653.6	656.37	752.07
Retained Earnings	2,223	2,152	1,923	1,676	1,447	1,240
Comprehensive Income & Other	4.26	4.24	3.84	2.82	-0.5	0.49
Total Common Equity	3,234	3,162	2,946	2,721	2,492	2,381
Minority Interest	28.72	29.67	30.68	69.84	68.47	65.96
Shareholders' Equity	3,262	3,192	2,977	2,791	2,560	2,447
Total Liabilities & Equity	12,629	12,639	11,794	11,784	9,993	8,571
Total Debt	5,132	4,951	4,858	5,080	4,486	3,500
Net Cash (Debt)	-4,675	-4,374	-4,252	-4,486	-4,071	-2,903
Net Cash Per Share	-11.92	-11.26	-10.99	-11.57	-10.51	-8.06
Filing Date Shares Outstanding	388.52	388.52	388.52	388.52	388.52	388.52
Total Common Shares Outstanding	388.52	388.52	388.52	388.52	388.52	388.52
Working Capital	1,297	1,265	1,292	1,447	1,307	1,298
Book Value Per Share	8.32	8.14	7.58	7.00	6.41	6.13
Tangible Book Value	2,585	2,512	2,302	2,254	2,034	1,984
Tangible Book Value Per Share	6.65	6.47	5.93	5.80	5.24	5.11
Buildings	-	1,443	1,001	899.38	858.76	816.23
Machinery	-	278.43	259.22	214.51	196.8	182.21
Construction In Progress	-	471.48	616.59	509.06	139.74	57.07

Source: S&P Global Market Intelligence. Standard template. Financial Sources.